What Chronic Hepatitis B Is and Typical Symptoms
Chronic hepatitis B is a persistent viral infection of the liver caused by the hepatitis B virus (HBV), clinically diagnosed when the hepatitis B surface antigen (HBsAg) remains detectable in the blood for six months or longer. Over time, continuous viral activity and the body's immune response cause ongoing hepatic inflammation. Without medical oversight, this chronic inflammation can lead to progressive scarring (fibrosis), cirrhosis, or hepatocellular carcinoma.
A primary challenge of chronic hepatitis B is that many people live with the condition for years without noticeable symptoms, while silent liver damage continues. When symptoms do occur, they are frequently non-specific and fluctuating. Patients may experience persistent fatigue, mild nausea, loss of appetite, aching joints, darker urine, or a dull ache in the upper right side of the abdomen. In more advanced stages where liver function becomes compromised, noticeable signs such as jaundice (yellowing of the skin and eyes), abdominal swelling (ascites), easy bruising, and leg swelling may appear. A comprehensive evaluation within a specialised gastroenterology department is crucial to establish whether the infection is currently active, dormant, or progressing.
How It Is Diagnosed: Tests and Records to Bring
Accurate evaluation of chronic hepatitis B requires a coordinated series of blood, molecular, and imaging assessments. When travelling to a hospital in Turkey for a clinical assessment, international patients typically undergo standard diagnostic procedures, which include:
- Serological testing: Confirmation of HBsAg, hepatitis B e-antigen (HBeAg), and their corresponding antibodies (anti-HBs, anti-HBe) to identify the specific phase of the infection. Testing for hepatitis delta (HDV) antibody is also conducted to rule out co-infection.
- Quantitative HBV DNA viral load: High-sensitivity polymerase chain reaction (PCR) tests to measure the exact amount of virus replicating in the bloodstream.
- Liver biochemistry: Routine blood panels assessing alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, albumin, and coagulation parameters (INR).
- Liver fibrosis assessment: Non-invasive transient elastography (such as FibroScan) to measure liver stiffness and estimate fibrosis without surgery, though a liver biopsy may occasionally be recommended if diagnostic ambiguity persists.
- Abdominal ultrasound: Detailed imaging to inspect liver architecture, evaluate blood flow through the portal vein, and screen for nodules, frequently arranged through dedicated check-ups and diagnostics services.
To facilitate an accurate review, patients should bring all available medical records from home. Important documents include historical HBV DNA viral load trends, past liver enzyme test results, previous abdominal ultrasound or scan reports, vaccination records, and a detailed summary of any past or ongoing antiviral therapies, including medication names, dosages, and durations.
Treatment Options and When Each Is Used
The goal of chronic hepatitis B management is to suppress viral replication, normalise liver enzyme levels, prevent the progression of fibrosis, and reduce the long-term risk of liver failure and liver cancer. Complete viral eradication is rare because the virus establishes a stable genetic reservoir known as covalently closed circular DNA (cccDNA) inside liver cell nuclei. Consequently, long-term viral suppression is the practical clinical aim. Treatment strategies are tailored to the individual and determined by the treating doctor after evaluating viral levels, enzyme activity, and the stage of liver fibrosis.
| Option |
Typically used when |
Things to know |
| Active Monitoring |
Patients have low or undetectable viral loads, normal ALT levels, and no significant liver fibrosis. |
Involves routine blood tests, viral load quantification, and liver ultrasound every three to six months without immediate medication. |
| Oral Antiviral Therapy (NUCs) |
Patients show elevated viral loads, persistent ALT elevation, or evidence of moderate-to-severe fibrosis or cirrhosis. |
First-line daily oral tablets (such as entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) effectively halt viral replication. Therapy is usually long term and must never be discontinued abruptly to prevent severe viral rebound. |
| Pegylated Interferon Alfa |
Selected younger patients with favourable viral characteristics, elevated ALT, and no signs of cirrhosis. |
Administered as weekly subcutaneous injections for a fixed duration of 48 weeks. It carries significant side effects, such as flu-like symptoms and mood changes, requiring frequent haematological monitoring. |
| Liver Cancer Surveillance |
All patients with established cirrhosis, advanced fibrosis, or a family history of liver cancer. |
Requires abdominal ultrasound and serum alpha-fetoprotein (AFP) testing every six months. If suspicious lesions are detected, immediate referral to oncology specialists is arranged. |
Planning Your Treatment in Turkey
Organising medical care in Turkey requires thoughtful preparation to ensure smooth diagnostic evaluation and long-term continuity. Before travelling, patients can submit their recent laboratory results and medical history for a preliminary review by the clinical team, confirming that travel for on-site evaluation is appropriate.
For an initial diagnostic workup—including specialist consultation, repeat serology, quantitative PCR testing, and transient elastography—patients typically need to stay in Turkey for 3 to 5 business days. This duration provides adequate time for laboratory processing, imaging, and a face-to-face consultation to discuss the specialist's clinical recommendations.
Because chronic hepatitis B requires continuous management, follow-up care in your home country is critical. Hospitals in Turkey supply comprehensive discharge reports, translated diagnostic findings, and clear treatment plans. Patients must share these documents with their local family physician or gastroenterologist to ensure regular blood monitoring, prescription renewals, and uninterrupted medical oversight.
When Travel Is Not Advisable and Warning Signs
Patients experiencing acute liver decompensation or sudden symptom exacerbation should not travel abroad. Such situations represent medical emergencies that require prompt evaluation and stabilisation at a local healthcare facility.
Warning signs that require urgent local medical attention include:
- Sudden onset or rapid worsening of jaundice, accompanied by profound weakness.
- Vomiting blood or passing black, tarry stools, which can indicate bleeding from oesophageal varices.
- New or progressive confusion, severe drowsiness, or cognitive changes, suggesting hepatic encephalopathy.
- Rapid swelling of the abdomen from fluid retention (ascites) or acute shortness of breath.
- High fever associated with abdominal tenderness or pain.
In the presence of any of these symptoms, immediate stabilisation at your nearest emergency department must always take precedence over international travel.
